Effect of bendamustine plus rituximab on relapsed extragastric mucosa-associated lymphoid tissue lymphoma

VernacularTitle:苯达莫司汀联合利妥昔单抗治疗胃外复发黏膜相关淋巴组织淋巴瘤
Author: Shaojie WU ; Sanfang TU ; Yaling ZHENG ; Lei WANG ; Chaoyang SONG
Publication Type:Journal Article
Keywords: Lymphoma,mucosa-associated lymphoid tissue; Recurrence; Rituximab; Bendamustine
From: Journal of Leukemia & Lymphoma 2015;24(10):598-600
CountryChina
Language:Chinese
Abstract: Objective To investigate the rituximab plus bendamustine (R-Benda) therapeutic effect for relapsed extragastric mucosa-associated lymphoid tissue (MALT) lymphoma.Methods Ten patients (three females and seven males) with relapsed extragastric MALT lymphoma undergoing therapy with R-Benda were defined.Bendamustine was given at a dose of 90 mg/m2 on days 2 and 3 in nine patients and at 70 mg/m2 in one patient, while all received 375 mg/m2 rituximab on day 1.Results Nine patients received six courses of therapy,while one patient discontinued therapy after five courses for personal reasons, while one elderly patient had progressive disease after three courses.Tolerance of therapy was excellent, and all except one patient responded.Eight patients achieved the complete remission, one achieved the partial remission, and one patient progressed.Toxicities were mild and mainly hematological.After a median follow-up of 24 months (range, 5-43 months), 9 patients were alive.Conclusion R-Benda regime has high activity and good tolerance for patients with relapsed extragastric MALT lymphoma.